Spirometric and anthropometric improvements in response to elexacaftor/tezacaftor/ivacaftor depending on age and lung disease severity

Spirometric and anthropometric improvements in response to elexacaftor/tezacaftor/ivacaftor depending on age and lung disease severity

Introduction: Triple-combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy with elexacaftor/tezacaftor/ivacaftor (ETI) was introduced in August 2020 in Germany for people with CF (pwCF) ≥12 years (yrs.) of age and in June 2021 for pwCF ≥6 yrs of age. In this single...

Full description

Bibliographic Details
Main Authors: Katharina Schütz, Sophia Theres Pallenberg, Julia Kontsendorn, David DeLuca, Cinja Sukdolak, Rebecca Minso, Tina Büttner, Martin Wetzke, Christian Dopfer, Annette Sauer-Heilborn, Felix C. Ringshausen, Sibylle Junge, Burkhard Tümmler, Gesine Hansen, Anna-Maria Dittrich
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-07-01
Series:Frontiers in Pharmacology
Subjects:
cystic fibrosis
BMI
elexacaftor/tezacaftor/ivacaftor
modulator
pediatric
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1171544/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1171544/full

Similar Items